Konstantin A. Kokushkin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Konstantin A. Kokushkin has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Tatiana N. Ermolaeva
Scientific and Practical Center for Clinical and Economic Analysis
9 shared publications - V. S. Krysanova
BIOTECH University
9 shared publications - A. D. Ermolaeva
Scientific and Practical Center for Clinical and Economic Analysis
8 shared publications - Marina Vladimirovna Zhuravleva
I.M. Sechenov First Moscow State Medical University (Sechenov University)
7 shared publications - M. V. Davydovskaya
City Clinical Hospital No. 24
5 shared publications - Ekaterina Vladimirovna Makarova
Russian University of Medicine
4 shared publications
Latest Publications
- Open Access
- 19 August 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 19 (2) , 234-243
Pharmacoeconomic evaluation of triple beclomethasone/glycopyrronium bromide/formoterol combination in the treatment of patients with moderate and severe chronic obstructive pulmonary disease
Objective : To conduct a pharmacoeconomic evaluation of the triple beclomethasone/formoterol/glycopyrronium fixed-dose combination (FDC) for the treatment of patients with moderate and severe chronic obstructive pulmonary disease (COPD) in healthcare institutions of the Moscow Region, Russia. Material and methods . A pharmacoepidemiological analysis was conducted using data from multiple levels of medical care for patients with COPD in the Moscow Region, including records data from the Territorial Fund for Compulsory Health Insurance (TFCHI) and data on subsidized drug provision. To characterize the frequency and structure of inpatient and outpatient care for COPD, a frequency analysis was performed. Direct costs of COPD pharmacotherapy were assessed, including expenditures associated with triple FDCs. In addition, a budget impact analysis was carried out to evaluate the provision of triple FDCs in a single delivery device. Results . During the analyzed period, 23,583 COPD patients received inpatient care and 7,314 received outpatient care, with total expenditures of 703,329,560 and 251,189,103 rubles, respectively. Analysis of subsidized drug provision showed that 757 patients (4.2% of all patients receiving COPD therapy) were treated with one of three triple FDCs: beclomethasone/glycopyrronium bromide/ formoterol, budesonide/glycopyrronium bromide/formoterol, or vilanterol/umeclidinium bromide/fluticasone furoate. Budget impact analysis demonstrated that two triple FDCs (budesonide/glycopyrronium bromide/formoterol and beclomethasone/glycopyrronium bromide/formoterol) were associated with identical costs: 2,763.20 rubles per month and 33,158.40 rubles per year. Treatment with the vilanterol/umeclidinium bromide/fluticasone furoate combination was associated with higher costs. Conclusion . Use of triple FDC of beclomethasone/glycopyrronium bromide/formoterol may help improve compliance to therapy among patients with COPD and is associated with lower costs for the Moscow Region healthcare system. This treatment approach is clinically and economically feasible.
- 19 August 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 19 (2) , 234-243
Open AccessPharmacoeconomic evaluation of triple beclomethasone/glycopyrronium bromide/formoterol combination in the treatment of patients with moderate and severe chronic obstructive pulmonary disease
Objective : To conduct a pharmacoeconomic evaluation of the triple beclomethasone/formoterol/glycopyrronium fixed-dose combination (FDC) for the treatment of patients with moderate and severe chronic obstructive pulmonary disease (COPD) in healthcare institutions of the Moscow Region, Russia. Material and methods . A pharmacoepidemiological analysis was conducted using data from multiple levels of medical care for patients with COPD in the Moscow Region, including records data from the Territorial Fund for Compulsory Health Insurance (TFCHI) and data on subsidized drug provision. To characterize the frequency and structure of inpatient and outpatient care for COPD, a frequency analysis was performed. Direct costs of COPD pharmacotherapy were assessed, including expenditures associated with triple FDCs. In addition, a budget impact analysis was carried out to evaluate the provision of triple FDCs in a single delivery device. Results . During the analyzed period, 23,583 COPD patients received inpatient care and 7,314 received outpatient care, with total expenditures of 703,329,560 and 251,189,103 rubles, respectively. Analysis of subsidized drug provision showed that 757 patients (4.2% of all patients receiving COPD therapy) were treated with one of three triple FDCs: beclomethasone/glycopyrronium bromide/ formoterol, budesonide/glycopyrronium bromide/formoterol, or vilanterol/umeclidinium bromide/fluticasone furoate. Budget impact analysis demonstrated that two triple FDCs (budesonide/glycopyrronium bromide/formoterol and beclomethasone/glycopyrronium bromide/formoterol) were associated with identical costs: 2,763.20 rubles per month and 33,158.40 rubles per year. Treatment with the vilanterol/umeclidinium bromide/fluticasone furoate combination was associated with higher costs. Conclusion . Use of triple FDC of beclomethasone/glycopyrronium bromide/formoterol may help improve compliance to therapy among patients with COPD and is associated with lower costs for the Moscow Region healthcare system. This treatment approach is clinically and economically feasible.
- 7 May 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 1 (19) , 5-14
Administration of tyrosyl-D-arginyl-phenylalanyl-glycine amide to manage postoperative pain in patients with type 2 diabetes mellitus and obesity: budget impact analysis
Objective : To evaluate the impact of administering tyrosyl-D-arginyl-phenylalanyl-glycine amide postoperatively to relieve pain in patients with type 2 diabetes mellitus (T2DM) and obesity on the compulsory health insurance system of Moscow Region. Material and methods . A pharmacoeconomic budget impact analysis covering a period of one year was conducted. The target population included T2DM and obesity patients aged over 18 years who received postoperative analgesic therapy (tyrosyl-D-arginyl-phenylalanylglycine amide, trimeperidine, or morphine). The regional budget impact analysis of drug therapy took into account the duration of analgesia, the incidence of complications and their treatment. A mathematical model was developed to calculate the direct medical costs of various postoperative analgesic regimens. The cost of pharmacotherapy and treatment of complications per patient during a course of medication was calculated. A sensitivity analysis of the obtained results was conducted. Results . A total of 1501 patients with T2DM and obesity underwent surgical treatment at the medical facilities of Moscow Region. The total sample of patients in the study was divided into three groups depending on the analgesic used. With the use of tyrosyl-D-arginylphenylalanyl-glycine amide, the incidence of complications in the analyzed patient population was almost four times lower compared to trimeperidine and morphine, and the cost of treating complications was almost three times lower. The total cost of treating one surgical patient experiencing a complication after the use of tyrosyl-D-arginyl-phenylalanyl-glycine amide amounted to 18,732.25 rubles, which is almost 1.3 times lower compared to other analgesic strategies. The budget impact analysis revealed the pharmacoeconomic feasibility of using tyrosyl-D-arginyl-phenylalanyl-glycine amide in postoperative analgesic therapy. Sensitivity analysis showed that the results were robust to changes in the initial parameters. Conclusion . Administration of tyrosyl-D-arginyl-phenylalanyl-glycine amide in the postoperative period leads to a proven reduction in the incidence of complications. This is a cost-effective approach to providing medical care to adult patients with T2DM and obesity.
- 7 May 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 1 (19) , 5-14
Administration of tyrosyl-D-arginyl-phenylalanyl-glycine amide to manage postoperative pain in patients with type 2 diabetes mellitus and obesity: budget impact analysis
Objective : To evaluate the impact of administering tyrosyl-D-arginyl-phenylalanyl-glycine amide postoperatively to relieve pain in patients with type 2 diabetes mellitus (T2DM) and obesity on the compulsory health insurance system of Moscow Region. Material and methods . A pharmacoeconomic budget impact analysis covering a period of one year was conducted. The target population included T2DM and obesity patients aged over 18 years who received postoperative analgesic therapy (tyrosyl-D-arginyl-phenylalanylglycine amide, trimeperidine, or morphine). The regional budget impact analysis of drug therapy took into account the duration of analgesia, the incidence of complications and their treatment. A mathematical model was developed to calculate the direct medical costs of various postoperative analgesic regimens. The cost of pharmacotherapy and treatment of complications per patient during a course of medication was calculated. A sensitivity analysis of the obtained results was conducted. Results . A total of 1501 patients with T2DM and obesity underwent surgical treatment at the medical facilities of Moscow Region. The total sample of patients in the study was divided into three groups depending on the analgesic used. With the use of tyrosyl-D-arginylphenylalanyl-glycine amide, the incidence of complications in the analyzed patient population was almost four times lower compared to trimeperidine and morphine, and the cost of treating complications was almost three times lower. The total cost of treating one surgical patient experiencing a complication after the use of tyrosyl-D-arginyl-phenylalanyl-glycine amide amounted to 18,732.25 rubles, which is almost 1.3 times lower compared to other analgesic strategies. The budget impact analysis revealed the pharmacoeconomic feasibility of using tyrosyl-D-arginyl-phenylalanyl-glycine amide in postoperative analgesic therapy. Sensitivity analysis showed that the results were robust to changes in the initial parameters. Conclusion . Administration of tyrosyl-D-arginyl-phenylalanyl-glycine amide in the postoperative period leads to a proven reduction in the incidence of complications. This is a cost-effective approach to providing medical care to adult patients with T2DM and obesity.
- Open Access
- 18 December 2025
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 13 (4) , 467-478
Drug Provision for Patients with Cutaneous Melanoma in Outpatient Settings: Regional Experience
INTRODUCTION. Despite its relatively low share in the structure of oncological incidence, cutaneous melanoma (CM) is one of the most cost-intensive nosologies. The emerging new combination treatment regimens require regular pharmacoeconomic monitoring. AIM. This study aimed to evaluate the current structure, dynamics, and costs of drug therapy in Moscow region over 2020–2022 based on pharmacoepidemiological and pharmacoeconomic analysis of subsidised drug provision in order to identify key regional trends. MATERIALS AND METHODS . Primary depersonalised data were obtained from patient medical records in the Unified Medical Information and Analytical System (EMIAS). The analysis included total number of patients and their clinical profile (gender, age, diagnosis code); for the drugs, international non-proprietary name, dosage form, dosage, number of packages sold, and total cost was analysed. Cost analysis considered both total cost and structure in terms of selected international non-proprietary names. An additional analysis was conducted for a three-year period. RESULTS. Data from 1,522 patients diagnosed with ICD-10 C43.0–43.9 were examined (465 patients in 2020, 526 patients in 2021, and 531 patients in 2022). Over the study period, the number of patients increased by 14%, with gender structure gradually changing and the ratio of men decreasing from 44.3% to 39.9%. Two-thirds of the patients received drug therapy for the primary disease. Total outpatient costs ranged from 407.6 million rubles in 2020 to 615.3 million rubles in 2022. CM share of drug therapy averaged 98% of the total cost. Over 2020–2022, the highest patient coverage, number of packages, and cost level was attributed to dabrafenib+trametinib and vemurafenib+cobimetinib combinations. They accounted for an average of 85% of all patients and almost 99% of all costs. Over the 3-year period, there was a twofold cost increase for dabrafenib and trametinib, with a comparable twofold cost decrease for vemurafenib and cobimetinib. CONCLUSIONS . Pharmacotherapy structure, dynamics, and cost has been evaluated in CM patients of Moscow region over 2020–2022. The obtained data can be used to optimise pharmacotherapy of CM patients at the regional level by widely introducing both clinical and pharmacoeconomic evaluation principles of treatment approaches.
- 18 December 2025
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 13 (4) , 467-478
Open AccessDrug Provision for Patients with Cutaneous Melanoma in Outpatient Settings: Regional Experience
INTRODUCTION. Despite its relatively low share in the structure of oncological incidence, cutaneous melanoma (CM) is one of the most cost-intensive nosologies. The emerging new combination treatment regimens require regular pharmacoeconomic monitoring. AIM. This study aimed to evaluate the current structure, dynamics, and costs of drug therapy in Moscow region over 2020–2022 based on pharmacoepidemiological and pharmacoeconomic analysis of subsidised drug provision in order to identify key regional trends. MATERIALS AND METHODS . Primary depersonalised data were obtained from patient medical records in the Unified Medical Information and Analytical System (EMIAS). The analysis included total number of patients and their clinical profile (gender, age, diagnosis code); for the drugs, international non-proprietary name, dosage form, dosage, number of packages sold, and total cost was analysed. Cost analysis considered both total cost and structure in terms of selected international non-proprietary names. An additional analysis was conducted for a three-year period. RESULTS. Data from 1,522 patients diagnosed with ICD-10 C43.0–43.9 were examined (465 patients in 2020, 526 patients in 2021, and 531 patients in 2022). Over the study period, the number of patients increased by 14%, with gender structure gradually changing and the ratio of men decreasing from 44.3% to 39.9%. Two-thirds of the patients received drug therapy for the primary disease. Total outpatient costs ranged from 407.6 million rubles in 2020 to 615.3 million rubles in 2022. CM share of drug therapy averaged 98% of the total cost. Over 2020–2022, the highest patient coverage, number of packages, and cost level was attributed to dabrafenib+trametinib and vemurafenib+cobimetinib combinations. They accounted for an average of 85% of all patients and almost 99% of all costs. Over the 3-year period, there was a twofold cost increase for dabrafenib and trametinib, with a comparable twofold cost decrease for vemurafenib and cobimetinib. CONCLUSIONS . Pharmacotherapy structure, dynamics, and cost has been evaluated in CM patients of Moscow region over 2020–2022. The obtained data can be used to optimise pharmacotherapy of CM patients at the regional level by widely introducing both clinical and pharmacoeconomic evaluation principles of treatment approaches.
- Open Access
- 28 October 2025
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- No. 3,p. 17-34
Regional experience in drug provision for patients with metastatic melanoma: a retrospective analysis of government procurement in Moscow region
Objective. To conduct a pharmacoepidemiologic and pharmacoeconomic analysis of government procurement of drugs for the treatment of metastatic melanoma (MM) in Moscow region during 2020–2022, assessing the compliance of real clinical practice with current recommendations and identifying opportunities to optimize drug provision for patients. Materials and methods. A retrospective pharmacoepidemiologic analysis of data on government procurement of key drugs used in the treatment of metastatic MM for the period 2020–2022 in Moscow region was performed, followed by a cost analysis. The analysis included 17 INNs: vemurafenib, vinblastine, dabrafenib, dacarbazine, imatinib, interferon alfa-2b, ipilimumab, carboplatin, cobimetinib, lomustine, nivolumab, paclitaxel, pembrolizumab, prolgolimab, temozolomide, trametinib, and cisplatin. The number of customers, trade names, dosage forms and packaging, number of packages purchased, cost per package, and total costs were analyzed. The average cost per 1 mg of active substance was separately evaluated over time. The results were processed using MS Excel 2019 and presented as absolute values and percentages. Results. Data from the procurement information system (https://zakupki.gov.ru) for 2020–2022 were analyzed, covering 1,831 government procurements of 17 INNs used for MM treatment in Moscow region healthcare facilities (622 in 2020, 686 in 2021, 523 in 2022). Total expenditure for the 17 INNs amounted to 4.8 billion rubles for the entire 2020–2022 period (1.3 billion in 2020, 1.8 billion in 2021, 1.7 billion rubles in 2022), with an increase in expenditure of more than 30 %. The cost structure was dominated by 3 INNs throughout the analyzed period — dabrafenib, nivolumab, and pembrolizumab, accounting for an average of 76.5 % of all expenses. During 2020–2022, pembrolizumab was the absolute leader (accounting for 39.2 % of purchases in 2020, 33.3 % in 2021, and 35.2 % in 2022), with cost growth of 1.2 times. Regarding the average cost per 1 mg of active substance, the most expensive MM treatments were: ipilimumab, trametinib, pembrolizumab, prolgolimab, and nivolumab. Over the 3-year period, among these INNs, only ipilimumab showed an increase in the average cost per 1 mg (+18.6 %), while prolgolimab showed a significant decrease (–17.2 %). When comparing different healthcare settings, there is a clear trend toward decreasing numbers of patients receiving oral targeted therapies in inpatient settings, while in outpatient settings the number of patients significantly increases, especially evident for the combination of dabrafenib and trametinib. Conclusions. Our study is the first example of a comprehensive pharmacoepidemiologic and pharmacoeconomic analysis covering various aspects of drug provision for patients with metastatic MM — government procurement, provision within preferential drug supply programs, and specialized medical care in hospital settings. The research results create an information base for making clinically and economically sound healthcare decisions, which can be used in developing regional oncology service programs, planning drug procurement, and improving the drug supply system for patients with metastatic MM.
- 28 October 2025
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- No. 3,p. 17-34
Open AccessRegional experience in drug provision for patients with metastatic melanoma: a retrospective analysis of government procurement in Moscow region
Objective. To conduct a pharmacoepidemiologic and pharmacoeconomic analysis of government procurement of drugs for the treatment of metastatic melanoma (MM) in Moscow region during 2020–2022, assessing the compliance of real clinical practice with current recommendations and identifying opportunities to optimize drug provision for patients. Materials and methods. A retrospective pharmacoepidemiologic analysis of data on government procurement of key drugs used in the treatment of metastatic MM for the period 2020–2022 in Moscow region was performed, followed by a cost analysis. The analysis included 17 INNs: vemurafenib, vinblastine, dabrafenib, dacarbazine, imatinib, interferon alfa-2b, ipilimumab, carboplatin, cobimetinib, lomustine, nivolumab, paclitaxel, pembrolizumab, prolgolimab, temozolomide, trametinib, and cisplatin. The number of customers, trade names, dosage forms and packaging, number of packages purchased, cost per package, and total costs were analyzed. The average cost per 1 mg of active substance was separately evaluated over time. The results were processed using MS Excel 2019 and presented as absolute values and percentages. Results. Data from the procurement information system (https://zakupki.gov.ru) for 2020–2022 were analyzed, covering 1,831 government procurements of 17 INNs used for MM treatment in Moscow region healthcare facilities (622 in 2020, 686 in 2021, 523 in 2022). Total expenditure for the 17 INNs amounted to 4.8 billion rubles for the entire 2020–2022 period (1.3 billion in 2020, 1.8 billion in 2021, 1.7 billion rubles in 2022), with an increase in expenditure of more than 30 %. The cost structure was dominated by 3 INNs throughout the analyzed period — dabrafenib, nivolumab, and pembrolizumab, accounting for an average of 76.5 % of all expenses. During 2020–2022, pembrolizumab was the absolute leader (accounting for 39.2 % of purchases in 2020, 33.3 % in 2021, and 35.2 % in 2022), with cost growth of 1.2 times. Regarding the average cost per 1 mg of active substance, the most expensive MM treatments were: ipilimumab, trametinib, pembrolizumab, prolgolimab, and nivolumab. Over the 3-year period, among these INNs, only ipilimumab showed an increase in the average cost per 1 mg (+18.6 %), while prolgolimab showed a significant decrease (–17.2 %). When comparing different healthcare settings, there is a clear trend toward decreasing numbers of patients receiving oral targeted therapies in inpatient settings, while in outpatient settings the number of patients significantly increases, especially evident for the combination of dabrafenib and trametinib. Conclusions. Our study is the first example of a comprehensive pharmacoepidemiologic and pharmacoeconomic analysis covering various aspects of drug provision for patients with metastatic MM — government procurement, provision within preferential drug supply programs, and specialized medical care in hospital settings. The research results create an information base for making clinically and economically sound healthcare decisions, which can be used in developing regional oncology service programs, planning drug procurement, and improving the drug supply system for patients with metastatic MM.
- Open Access
- 28 October 2025
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- No. 3,p. 4-16
Analysis of drug therapy for patients with metastatic melanoma of the skin using the example of the Moscow region
Objective. To conduct a pharmacoepidemiological and pharmacoeconomic analysis of specialized inpatient medical care provided to patients with metastatic melanoma (MM) in the Moscow Region during 2020–2022. Materials and methods. A retrospective pharmacoepidemiological analysis of specialized inpatient medical care provided to patients with MM in Moscow Region during 2020–2022 was performed, followed by a cost analysis. The study analyzed the total number of patients receiving various drug therapy regimens with their main clinical characteristics (gender, age, diagnosis code), the total number of hospitalizations considering their structure (inpatient/day hospital), the average number of hospitalizations per patient, and the average length of hospital stay. The cost analysis examined both total costs and their structure across different drug regimens. The results were processed using Microsoft Excel 2019 and are presented as absolute values and percentages (%). Results. This study examined 10,609 cases of specialized and primary specialized inpatient medical care provided to patients diagnosed with ICD-10 C43.0–43.9 in healthcare facilities of the Moscow Region from 2020 to 2022 (4,471 cases in 2020, 2,970 cases in 2021, and 3,168 cases in 2022). During the analysis period, the number of patients with MM receiving inpatient treatment decreased by 29 %, whereas the average number of hospitalizations per patient was 6.2 in 2020, 5.2 in 2021, and 6.3 in 2022. The hospitalization structure showed a trend toward decreasing the proportion of care provided in the 24-hour inpatient setting. The total costs of specialized medical care for patients with MM ranged from 1.8 billion rubles (2020) to 1.1 billion rubles (2022). In 2020, the three most demanded regimens by number of patients and hospitalizations were nivolumab, pembrolizumab, and dabrafenib + trametinib combination. This pattern persisted until 2021. In 2022, a shift in MM pharmacotherapy priorities was observed — alongside nivolumab and pembrolizumab regimens, prolgolimab became one of the most demanded treatments. These regimens were administered to more than 80 % of patients with MM at each time interval. Cost analysis revealed that in 2020, the same regimens that led in patient numbers also accounted for more than 95 % of total costs. In 2021 and 2022, the costliest regimens were those using nivolumab, pembrolizumab, and the combination of ipilimumab and nivolumab, accounting for more than 90 % of the costs. Drug therapy using pembrolizumab and nivolumab became the absolute leader both in patient numbers and costs throughout the entire analysis period, with nivolumab showing a gradual decrease in both patient numbers (1.7-fold) and cost levels (3.2-fold), while pembrolizumab showed the opposite trend —growth (1.5-fold and 1.9-fold, respectively). Conclusions. The results of this analysis can contribute to further improvement of the regional medical care system for patients with MM, thereby enhancing the quality and accessibility of modern and highly effective pharmacotherapy approaches.
- 28 October 2025
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- No. 3,p. 4-16
Open AccessAnalysis of drug therapy for patients with metastatic melanoma of the skin using the example of the Moscow region
Objective. To conduct a pharmacoepidemiological and pharmacoeconomic analysis of specialized inpatient medical care provided to patients with metastatic melanoma (MM) in the Moscow Region during 2020–2022. Materials and methods. A retrospective pharmacoepidemiological analysis of specialized inpatient medical care provided to patients with MM in Moscow Region during 2020–2022 was performed, followed by a cost analysis. The study analyzed the total number of patients receiving various drug therapy regimens with their main clinical characteristics (gender, age, diagnosis code), the total number of hospitalizations considering their structure (inpatient/day hospital), the average number of hospitalizations per patient, and the average length of hospital stay. The cost analysis examined both total costs and their structure across different drug regimens. The results were processed using Microsoft Excel 2019 and are presented as absolute values and percentages (%). Results. This study examined 10,609 cases of specialized and primary specialized inpatient medical care provided to patients diagnosed with ICD-10 C43.0–43.9 in healthcare facilities of the Moscow Region from 2020 to 2022 (4,471 cases in 2020, 2,970 cases in 2021, and 3,168 cases in 2022). During the analysis period, the number of patients with MM receiving inpatient treatment decreased by 29 %, whereas the average number of hospitalizations per patient was 6.2 in 2020, 5.2 in 2021, and 6.3 in 2022. The hospitalization structure showed a trend toward decreasing the proportion of care provided in the 24-hour inpatient setting. The total costs of specialized medical care for patients with MM ranged from 1.8 billion rubles (2020) to 1.1 billion rubles (2022). In 2020, the three most demanded regimens by number of patients and hospitalizations were nivolumab, pembrolizumab, and dabrafenib + trametinib combination. This pattern persisted until 2021. In 2022, a shift in MM pharmacotherapy priorities was observed — alongside nivolumab and pembrolizumab regimens, prolgolimab became one of the most demanded treatments. These regimens were administered to more than 80 % of patients with MM at each time interval. Cost analysis revealed that in 2020, the same regimens that led in patient numbers also accounted for more than 95 % of total costs. In 2021 and 2022, the costliest regimens were those using nivolumab, pembrolizumab, and the combination of ipilimumab and nivolumab, accounting for more than 90 % of the costs. Drug therapy using pembrolizumab and nivolumab became the absolute leader both in patient numbers and costs throughout the entire analysis period, with nivolumab showing a gradual decrease in both patient numbers (1.7-fold) and cost levels (3.2-fold), while pembrolizumab showed the opposite trend —growth (1.5-fold and 1.9-fold, respectively). Conclusions. The results of this analysis can contribute to further improvement of the regional medical care system for patients with MM, thereby enhancing the quality and accessibility of modern and highly effective pharmacotherapy approaches.
- 7 July 2025
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 65 (6) , 23-33
Pharmacoeconomic Aspects of Using New Generation Drugs Of PCSK-9 Inhibitor and Acting on The Effect of Ribonucleic Acid Interference Classes in The Treatment of Patients With Hypercholesterolemia at High Risk of Cardiovascular Events
Aim Clinical and economic analysis of the feasibility of using new-generation drugs of the PCSK-9 inhibitor class (alirocumab and evolocumab) and the drugs that utilize in their action the effect of ribonucleic acid interference (inclisiran) in the treatment of patients with a high risk of cardiovascular events in medical organizations of the Moscow Region (MR). Material and methods Based on statistical and literature data on morbidity, as well as data from real-life practice about using alirocumab, evolocumab, and inclisiran in medical organizations of the MR, populations of patients with hypercholesterolemia and cardiovascular pathology were identified in that region. Two analytical models were developed that include the structure and number of patients receiving a combination therapy (high-dose statins + ezetimibe + alirocumab/evolocumab/inclisiran). To estimate the economic feasibility of the treatment with innovative drugs, direct medical costs were calculated for various therapeutic regimens. The cost of pharmacotherapy was calculated per patient per one-year course. A budget impact analysis (BIA) and a sensitivity analysis of the results were performed. The modeling period of the study was 3 years. Results The number of patients in different populations receiving the combination therapy will be 12,228 and 895 people in the first year, and 12,973 and 950 people in the third year, taking into account the determined increase in the patient number. The total costs of treating one patient with hypercholesterolemia and cardiovascular diseases during the first year of therapy with inclisiran are 23.31 and 27.66% lower than with evolocumab and alirocumab, respectively. The BIA revealed a slight increase in the total cost of treating patients in each population (by 1.39 and 1.69% compared to 2024). The increase in the regional budget will be related only with the annual increase in the number of patients with hypercholesterolemia. The sensitivity analysis showed the robustness of the results to changes in the initial parameter values. Conclusion The treatment of patients with dyslipidemia and high risk of cardiovascular events with alirocumab/evolocumab/inclisiran as part of the combination therapy is an economically justified strategy in the settings of the regional healthcare system.
- 7 July 2025
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 65 (6) , 23-33
Pharmacoeconomic Aspects of Using New Generation Drugs Of PCSK-9 Inhibitor and Acting on The Effect of Ribonucleic Acid Interference Classes in The Treatment of Patients With Hypercholesterolemia at High Risk of Cardiovascular Events
Aim Clinical and economic analysis of the feasibility of using new-generation drugs of the PCSK-9 inhibitor class (alirocumab and evolocumab) and the drugs that utilize in their action the effect of ribonucleic acid interference (inclisiran) in the treatment of patients with a high risk of cardiovascular events in medical organizations of the Moscow Region (MR). Material and methods Based on statistical and literature data on morbidity, as well as data from real-life practice about using alirocumab, evolocumab, and inclisiran in medical organizations of the MR, populations of patients with hypercholesterolemia and cardiovascular pathology were identified in that region. Two analytical models were developed that include the structure and number of patients receiving a combination therapy (high-dose statins + ezetimibe + alirocumab/evolocumab/inclisiran). To estimate the economic feasibility of the treatment with innovative drugs, direct medical costs were calculated for various therapeutic regimens. The cost of pharmacotherapy was calculated per patient per one-year course. A budget impact analysis (BIA) and a sensitivity analysis of the results were performed. The modeling period of the study was 3 years. Results The number of patients in different populations receiving the combination therapy will be 12,228 and 895 people in the first year, and 12,973 and 950 people in the third year, taking into account the determined increase in the patient number. The total costs of treating one patient with hypercholesterolemia and cardiovascular diseases during the first year of therapy with inclisiran are 23.31 and 27.66% lower than with evolocumab and alirocumab, respectively. The BIA revealed a slight increase in the total cost of treating patients in each population (by 1.39 and 1.69% compared to 2024). The increase in the regional budget will be related only with the annual increase in the number of patients with hypercholesterolemia. The sensitivity analysis showed the robustness of the results to changes in the initial parameter values. Conclusion The treatment of patients with dyslipidemia and high risk of cardiovascular events with alirocumab/evolocumab/inclisiran as part of the combination therapy is an economically justified strategy in the settings of the regional healthcare system.
- Open Access
- 24 June 2024
- Published by Rostov State Medical University in South Russian Journal of Therapeutic Practice
- Vol. 5 (2) , 38-47
Clinical and economic studies of pharmacotherapy for multiple myeloma: literature review data
Among hematological diseases, Multiple myeloma (MM) is the second most common malignancy in adults worldwide. In the vast majority of cases, MM remains incurable, despite improvements in progression-free survival and overall survival due to advances in pharmacotherapy, as well as the emergence of innovative drugs in recent years. Unfortunately, this does not prevent patients from relapse and, ultimately, multidrug resistance and poor prognosis. In conditions of limited funding, one of the determining factors for the success of therapy is the cost of treatment. There is a need to conduct a clinical and economic analysis of the use of targeted drugs to determine the most economically feasible treatment option. The purpose of the review is to provide an overview of current and experimental treatments for relapsed/refractory MM (RRMM), with an emphasis on their pharmacoeconomic availability to assist clinicians in their decision-making process. Let's look at the latest data that will help improve approaches to the treatment of this still incurable disease and analyze pharmacoeconomic studies of modern expensive treatment regimens for RRMM in various countries.
- 24 June 2024
- Published by Rostov State Medical University in South Russian Journal of Therapeutic Practice
- Vol. 5 (2) , 38-47
Open AccessClinical and economic studies of pharmacotherapy for multiple myeloma: literature review data
Among hematological diseases, Multiple myeloma (MM) is the second most common malignancy in adults worldwide. In the vast majority of cases, MM remains incurable, despite improvements in progression-free survival and overall survival due to advances in pharmacotherapy, as well as the emergence of innovative drugs in recent years. Unfortunately, this does not prevent patients from relapse and, ultimately, multidrug resistance and poor prognosis. In conditions of limited funding, one of the determining factors for the success of therapy is the cost of treatment. There is a need to conduct a clinical and economic analysis of the use of targeted drugs to determine the most economically feasible treatment option. The purpose of the review is to provide an overview of current and experimental treatments for relapsed/refractory MM (RRMM), with an emphasis on their pharmacoeconomic availability to assist clinicians in their decision-making process. Let's look at the latest data that will help improve approaches to the treatment of this still incurable disease and analyze pharmacoeconomic studies of modern expensive treatment regimens for RRMM in various countries.
- 16 June 2024
- Published by Farmarus Print Media in Russian Journal of Allergy
- Vol. 21 (2) , 254-264
Experience of lanadelumab usage for long-term prophylaxis of attacks in hereditary angioedema in patients of the Moscow region
BACKGROUND: Hereditary angioedema is a rare disease with high frequency for orphan diseases. The autosomal dominant type of inheritance leads to a significant number of affected patients in families. Angioedema attacks significantly impair the quality of life. hereditary angioedema causes life-threatening conditions which depend on edema’s localization. AIM: To evaluate the efficacy and safety of lanadelumab for long-term prophylaxis in hereditary angioedema in routine practice. MATERIALS AND METHODS: 16 patients with hereditary angioedema were enrolled in the observational single-center study. The data were researched: sex, patients age, age of symptoms onset, efficacy of previous methods of therapy, type of hereditary angioedema, genetics of the disease, contraindications for other prophylaxis methods. The efficacy of therapy was evaluated according to the duration of the course, the frequency of administration, the number of attacks of edema during the period of observation, and the improvement of the quality of life according to the AAS28 scale. Safety of use was evaluated by the presence of adverse events during the investigation. RESULTS: The long-term prophylaxis with lanadelumab was effectively and safety for all of 16 patients. Single attacks during of therapy were provoked by the influence of significant triggers. Life-threatening attacks were not registered. The frequency of lanadelumab injections was reduced after 12 months of usage for 50% of patients. The improvement of the quality of life (from 6 to 38 according to AAS28 scale) was confirmed for all patients. Adverse events weren’t registered during the period of treatment. CONCLUSION: The long-term prophylaxis of edema in hereditary angioedema with lanadelumab usage was approved as efficiently and safety.
- 16 June 2024
- Published by Farmarus Print Media in Russian Journal of Allergy
- Vol. 21 (2) , 254-264
Experience of lanadelumab usage for long-term prophylaxis of attacks in hereditary angioedema in patients of the Moscow region
BACKGROUND: Hereditary angioedema is a rare disease with high frequency for orphan diseases. The autosomal dominant type of inheritance leads to a significant number of affected patients in families. Angioedema attacks significantly impair the quality of life. hereditary angioedema causes life-threatening conditions which depend on edema’s localization. AIM: To evaluate the efficacy and safety of lanadelumab for long-term prophylaxis in hereditary angioedema in routine practice. MATERIALS AND METHODS: 16 patients with hereditary angioedema were enrolled in the observational single-center study. The data were researched: sex, patients age, age of symptoms onset, efficacy of previous methods of therapy, type of hereditary angioedema, genetics of the disease, contraindications for other prophylaxis methods. The efficacy of therapy was evaluated according to the duration of the course, the frequency of administration, the number of attacks of edema during the period of observation, and the improvement of the quality of life according to the AAS28 scale. Safety of use was evaluated by the presence of adverse events during the investigation. RESULTS: The long-term prophylaxis with lanadelumab was effectively and safety for all of 16 patients. Single attacks during of therapy were provoked by the influence of significant triggers. Life-threatening attacks were not registered. The frequency of lanadelumab injections was reduced after 12 months of usage for 50% of patients. The improvement of the quality of life (from 6 to 38 according to AAS28 scale) was confirmed for all patients. Adverse events weren’t registered during the period of treatment. CONCLUSION: The long-term prophylaxis of edema in hereditary angioedema with lanadelumab usage was approved as efficiently and safety.
- 17 March 2024
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 46 (1)
Clinical and economic effectiveness of thrombopoietin receptor agonists in the treatment of primary immune thrombocytopenia in the Moscow region
Objective. To perfom cost-effectiveness and budget impact analysis (BIA) of thrombopoietin receptor agonists (romiplostim, eltrombopag and avatrombopag) in the treatment of adults with idiopathic thrombocytopenic purpura (ITP) in hospitals of the Moscow region (MR). Material and methods. The effectiveness criterion in cost-effectiveness analysis was the patient’s response to therapy. We prepared a model of providing care to adults with ITP. This model included assessment of economic and clinical effectiveness of various treatment strategies, as well as long-term prediction of budget expenditures for MR healthcare system following changes in appropriate practice. The study was conducted from the perspective of regional healthcare system. Therefore, we analyzed only direct medical costs for medications, drug administration, therapy monitoring, «rescue therapy» and treatment of major bleeding. Results. Cost-effectiveness analysis established the advantage of avatrombopag (981 305.46 rubles) over eltrombopag (1 030 500.81 rubles) and romiplostim (1 918 933.40 rubles) The difference in cost effectiveness of avatrombopag was 1 215.951.77 and 10 726 613.25 rubles, respectively. BIA showed that pharmacotherapy with thrombopoietin receptor agonists will increase total costs by 22.47% by 2025 considering annual increase in the number of patients with ITP and changes in proportions of the analyzed drugs. Treatment strategy for avatrombopag will be economically feasible throughout the entire period. Conclusion. Avatrombopag therapy is a clinically and economically justified strategy for medical care in adults with ITP in the MR.
- 17 March 2024
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 46 (1)
Clinical and economic effectiveness of thrombopoietin receptor agonists in the treatment of primary immune thrombocytopenia in the Moscow region
Objective. To perfom cost-effectiveness and budget impact analysis (BIA) of thrombopoietin receptor agonists (romiplostim, eltrombopag and avatrombopag) in the treatment of adults with idiopathic thrombocytopenic purpura (ITP) in hospitals of the Moscow region (MR). Material and methods. The effectiveness criterion in cost-effectiveness analysis was the patient’s response to therapy. We prepared a model of providing care to adults with ITP. This model included assessment of economic and clinical effectiveness of various treatment strategies, as well as long-term prediction of budget expenditures for MR healthcare system following changes in appropriate practice. The study was conducted from the perspective of regional healthcare system. Therefore, we analyzed only direct medical costs for medications, drug administration, therapy monitoring, «rescue therapy» and treatment of major bleeding. Results. Cost-effectiveness analysis established the advantage of avatrombopag (981 305.46 rubles) over eltrombopag (1 030 500.81 rubles) and romiplostim (1 918 933.40 rubles) The difference in cost effectiveness of avatrombopag was 1 215.951.77 and 10 726 613.25 rubles, respectively. BIA showed that pharmacotherapy with thrombopoietin receptor agonists will increase total costs by 22.47% by 2025 considering annual increase in the number of patients with ITP and changes in proportions of the analyzed drugs. Treatment strategy for avatrombopag will be economically feasible throughout the entire period. Conclusion. Avatrombopag therapy is a clinically and economically justified strategy for medical care in adults with ITP in the MR.
- Open Access
- 30 December 2023
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 16 (4) , 537-549
Pharmacoeconomic analysis of using empegfilgrastim for the treatment of early and locally advanced HER2+ breast cancer in the Russian Federation
Objective: to assess budget impact of using empegfilgrastim for the prevention of febrile neutropenia in patients with early and locally advanced human epidermal growth factor receptor 2 positive (HER2+) breast cancer who receive neoadjuvant “docetaxel / carboplatin / trastuzumab + pertuzumab” regimen, considering possible subsequent adjuvant therapy with trastuzumab emtansine or trastuzumab within the Russian healthcare system.Material and methods. We searched and analyzed published clinical, epidemiological and pharmacoeconomic studies as well as regulatory and legal documents. A decision tree model was constructed to reflect the probabilities of switching to different adjuvant therapy regimens depending on the achievement of pathomorphological complete response in patients with early and locally advanced HER2+ breast cancer. The budget impact analysis was carried out comparing two primary prophylactic options, empegfilgrastim and filgrastim.Results. Despite the higher costs of prevention with empegfilgrastim compared to filgrastim (249 vs. 134 thousand rubles), due to the higher rate of achieving a pathomorphological complete response and, accordingly, fewer cases requiring adjuvant therapy with the more expensive trastuzumab emtanzine, savings of 916 thousand rubles per 1 patient per 1 year of therapy are possible. In general, prophylaxis in the target population diagnosed with early and locally advanced HER2+ breast cancer using empegfilgrastim will result in a cost reduction of 9.4 billion rubles per 1 year compared to filgrastim.Conclusion. Empegfilgrastim prophylaxis, despite its higher annual cost, is an efficient option within the Russian healthcare system. In addition to reducing the incidence of febrile neutropenia, the frequency and dose of chemotherapy are preserved, resulting in increased efficacy of the primary therapy.
- 30 December 2023
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 16 (4) , 537-549
Open AccessPharmacoeconomic analysis of using empegfilgrastim for the treatment of early and locally advanced HER2+ breast cancer in the Russian Federation
Objective: to assess budget impact of using empegfilgrastim for the prevention of febrile neutropenia in patients with early and locally advanced human epidermal growth factor receptor 2 positive (HER2+) breast cancer who receive neoadjuvant “docetaxel / carboplatin / trastuzumab + pertuzumab” regimen, considering possible subsequent adjuvant therapy with trastuzumab emtansine or trastuzumab within the Russian healthcare system.Material and methods. We searched and analyzed published clinical, epidemiological and pharmacoeconomic studies as well as regulatory and legal documents. A decision tree model was constructed to reflect the probabilities of switching to different adjuvant therapy regimens depending on the achievement of pathomorphological complete response in patients with early and locally advanced HER2+ breast cancer. The budget impact analysis was carried out comparing two primary prophylactic options, empegfilgrastim and filgrastim.Results. Despite the higher costs of prevention with empegfilgrastim compared to filgrastim (249 vs. 134 thousand rubles), due to the higher rate of achieving a pathomorphological complete response and, accordingly, fewer cases requiring adjuvant therapy with the more expensive trastuzumab emtanzine, savings of 916 thousand rubles per 1 patient per 1 year of therapy are possible. In general, prophylaxis in the target population diagnosed with early and locally advanced HER2+ breast cancer using empegfilgrastim will result in a cost reduction of 9.4 billion rubles per 1 year compared to filgrastim.Conclusion. Empegfilgrastim prophylaxis, despite its higher annual cost, is an efficient option within the Russian healthcare system. In addition to reducing the incidence of febrile neutropenia, the frequency and dose of chemotherapy are preserved, resulting in increased efficacy of the primary therapy.